Please login to the form below

Not currently logged in
Email:
Password:

Dovato

This page shows the latest Dovato news and features for those working in and with pharma, biotech and healthcare.

GSK considers more divestments to help R&D push

GSK considers more divestments to help R&D push

There was an acceleration in sales of ViiV’s new two-drug combinations Juluca (dolutegravir/rilpivirine) and Dovato (dolutegravir/lamivudine) however, which GSK sees as the main weapon in its arsenal

Latest news

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... ViiV – which is majority owned by

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    All eyes now are on Dovato (dolutegravir/lamivudine), GSK’s new two-drug combination that was recently the first ever once-a-day two-drug regimen to be approved for treating ... ViiV chairman David Redfern said Juluca and Dovato – alongside GSK’s

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    Dovato (dolutegravir/lamivudine) is marketed by GSK-led joint venture ViiV, and is the first ever once-a-day two-drug STR for treating treatment-naïve patients. ... seen whether or not the same will be true for 2-drug STRs such as Dovato.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....